WO2022208156A1 - Pharmaceutical composition of molnupiravir - Google Patents
Pharmaceutical composition of molnupiravir Download PDFInfo
- Publication number
- WO2022208156A1 WO2022208156A1 PCT/IB2021/058519 IB2021058519W WO2022208156A1 WO 2022208156 A1 WO2022208156 A1 WO 2022208156A1 IB 2021058519 W IB2021058519 W IB 2021058519W WO 2022208156 A1 WO2022208156 A1 WO 2022208156A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- molnupiravir
- pharmaceutical composition
- pharmaceutically acceptable
- dosage form
- pharmaceutical
- Prior art date
Links
- HTNPEHXGEKVIHG-ZJTJHKMLSA-N molnupiravir Chemical group CC(C)C(=O)OC[C@H]1O[C@H](C(O)C1O)N1C=C\C(NC1=O)=N\O HTNPEHXGEKVIHG-ZJTJHKMLSA-N 0.000 title claims abstract description 76
- 229940075124 molnupiravir Drugs 0.000 title claims abstract description 75
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 46
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 44
- 150000003839 salts Chemical class 0.000 claims abstract description 41
- 239000000203 mixture Substances 0.000 claims description 56
- 239000002775 capsule Substances 0.000 claims description 22
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 12
- 239000003826 tablet Substances 0.000 claims description 12
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 11
- 239000011230 binding agent Substances 0.000 claims description 11
- 208000036142 Viral infection Diseases 0.000 claims description 10
- 239000008187 granular material Substances 0.000 claims description 10
- 230000009385 viral infection Effects 0.000 claims description 10
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical class C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 9
- 239000003085 diluting agent Substances 0.000 claims description 8
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 claims description 8
- 229940045902 sodium stearyl fumarate Drugs 0.000 claims description 8
- 239000002552 dosage form Substances 0.000 claims description 7
- 239000006186 oral dosage form Substances 0.000 claims description 7
- 239000001913 cellulose Chemical class 0.000 claims description 6
- 239000000314 lubricant Substances 0.000 claims description 6
- 235000019359 magnesium stearate Nutrition 0.000 claims description 6
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 6
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 6
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 5
- 229920000881 Modified starch Chemical class 0.000 claims description 5
- 235000021355 Stearic acid Nutrition 0.000 claims description 5
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 claims description 5
- 235000013539 calcium stearate Nutrition 0.000 claims description 5
- 239000008116 calcium stearate Substances 0.000 claims description 5
- 229920002678 cellulose Chemical class 0.000 claims description 5
- 235000010980 cellulose Nutrition 0.000 claims description 5
- 206010022000 influenza Diseases 0.000 claims description 5
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 5
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 5
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 5
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 5
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 5
- 239000008117 stearic acid Substances 0.000 claims description 5
- 239000000725 suspension Substances 0.000 claims description 5
- 241000711573 Coronaviridae Species 0.000 claims description 4
- 201000011001 Ebola Hemorrhagic Fever Diseases 0.000 claims description 4
- 229920003081 Povidone K 30 Polymers 0.000 claims description 4
- 241000710884 Powassan virus Species 0.000 claims description 4
- 239000007894 caplet Substances 0.000 claims description 4
- 229940075614 colloidal silicon dioxide Drugs 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 4
- 239000006188 syrup Substances 0.000 claims description 4
- 235000020357 syrup Nutrition 0.000 claims description 4
- 241000710929 Alphavirus Species 0.000 claims description 3
- 241000711950 Filoviridae Species 0.000 claims description 3
- 241000710831 Flavivirus Species 0.000 claims description 3
- 235000010643 Leucaena leucocephala Nutrition 0.000 claims description 3
- 241000711504 Paramyxoviridae Species 0.000 claims description 3
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 3
- 239000007884 disintegrant Substances 0.000 claims description 3
- 239000008188 pellet Substances 0.000 claims description 3
- 239000006187 pill Substances 0.000 claims description 3
- 229940069328 povidone Drugs 0.000 claims description 3
- 229920002785 Croscarmellose sodium Polymers 0.000 claims description 2
- 241000712464 Orthomyxoviridae Species 0.000 claims description 2
- 241000724205 Rice stripe tenuivirus Species 0.000 claims description 2
- 229960001681 croscarmellose sodium Drugs 0.000 claims description 2
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims description 2
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 claims 2
- 241000220479 Acacia Species 0.000 claims 1
- 239000003086 colorant Substances 0.000 claims 1
- 229960005191 ferric oxide Drugs 0.000 claims 1
- 235000013980 iron oxide Nutrition 0.000 claims 1
- 235000019426 modified starch Nutrition 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 19
- 238000002360 preparation method Methods 0.000 abstract description 13
- 230000008569 process Effects 0.000 abstract description 6
- 150000001875 compounds Chemical class 0.000 description 16
- 239000000463 material Substances 0.000 description 13
- 238000009472 formulation Methods 0.000 description 12
- 239000000243 solution Substances 0.000 description 10
- 238000003756 stirring Methods 0.000 description 9
- 239000003814 drug Substances 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- -1 edisylate Chemical compound 0.000 description 8
- 208000025721 COVID-19 Diseases 0.000 description 7
- 239000004480 active ingredient Substances 0.000 description 7
- 238000004090 dissolution Methods 0.000 description 7
- 238000005469 granulation Methods 0.000 description 7
- 230000003179 granulation Effects 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 239000008213 purified water Substances 0.000 description 6
- 239000002253 acid Substances 0.000 description 5
- 229960000913 crospovidone Drugs 0.000 description 5
- 239000000499 gel Substances 0.000 description 5
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 5
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 5
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 4
- 230000001174 ascending effect Effects 0.000 description 4
- 229940126587 biotherapeutics Drugs 0.000 description 4
- 230000009246 food effect Effects 0.000 description 4
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 4
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 4
- 229940071676 hydroxypropylcellulose Drugs 0.000 description 4
- 238000005461 lubrication Methods 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 239000002674 ointment Substances 0.000 description 4
- 239000008184 oral solid dosage form Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- 241000282339 Mustela Species 0.000 description 3
- XCUAIINAJCDIPM-XVFCMESISA-N N(4)-hydroxycytidine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=NO)C=C1 XCUAIINAJCDIPM-XVFCMESISA-N 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 238000011049 filling Methods 0.000 description 3
- 235000021471 food effect Nutrition 0.000 description 3
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 3
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 3
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 3
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 3
- 229920000609 methyl cellulose Polymers 0.000 description 3
- 235000010981 methylcellulose Nutrition 0.000 description 3
- 239000001923 methylcellulose Substances 0.000 description 3
- 229960002900 methylcellulose Drugs 0.000 description 3
- HTNPEHXGEKVIHG-QCNRFFRDSA-N molnupiravir Chemical compound C(OC(=O)C(C)C)[C@H]1O[C@H]([C@@H]([C@@H]1O)O)N1C(=O)N=C(NO)C=C1 HTNPEHXGEKVIHG-QCNRFFRDSA-N 0.000 description 3
- 239000008203 oral pharmaceutical composition Substances 0.000 description 3
- 239000006201 parenteral dosage form Substances 0.000 description 3
- 230000035699 permeability Effects 0.000 description 3
- 239000000902 placebo Substances 0.000 description 3
- 229940068196 placebo Drugs 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 238000003757 reverse transcription PCR Methods 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229940083542 sodium Drugs 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 235000010413 sodium alginate Nutrition 0.000 description 3
- 239000000661 sodium alginate Substances 0.000 description 3
- 229940005550 sodium alginate Drugs 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000007909 solid dosage form Substances 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 229940032147 starch Drugs 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000006208 topical dosage form Substances 0.000 description 3
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- 201000009182 Chikungunya Diseases 0.000 description 2
- 208000004293 Chikungunya Fever Diseases 0.000 description 2
- 239000001856 Ethyl cellulose Substances 0.000 description 2
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- 240000007472 Leucaena leucocephala Species 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 241000710959 Venezuelan equine encephalitis virus Species 0.000 description 2
- 208000001455 Zika Virus Infection Diseases 0.000 description 2
- 241000907316 Zika virus Species 0.000 description 2
- 208000035332 Zika virus disease Diseases 0.000 description 2
- 208000020329 Zika virus infectious disease Diseases 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 239000000783 alginic acid Substances 0.000 description 2
- 229960001126 alginic acid Drugs 0.000 description 2
- 150000004781 alginic acids Chemical class 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229960005069 calcium Drugs 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000007907 direct compression Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000012738 dissolution medium Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 238000007908 dry granulation Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 235000019325 ethyl cellulose Nutrition 0.000 description 2
- 229920001249 ethyl cellulose Polymers 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000001125 extrusion Methods 0.000 description 2
- 229910021485 fumed silica Inorganic materials 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 2
- 238000010255 intramuscular injection Methods 0.000 description 2
- 239000007927 intramuscular injection Substances 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 239000008297 liquid dosage form Substances 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 229940091250 magnesium supplement Drugs 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 229960003975 potassium Drugs 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- 239000007962 solid dispersion Substances 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 239000012049 topical pharmaceutical composition Substances 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- YGTUPRIZNBMOFV-UHFFFAOYSA-N 2-(4-hydroxybenzoyl)benzoic acid Chemical compound OC(=O)C1=CC=CC=C1C(=O)C1=CC=C(O)C=C1 YGTUPRIZNBMOFV-UHFFFAOYSA-N 0.000 description 1
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 241000710946 Barmah Forest virus Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- 241001678559 COVID-19 virus Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 241001502567 Chikungunya virus Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 208000032170 Congenital Abnormalities Diseases 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- DSLZVSRJTYRBFB-LLEIAEIESA-N D-glucaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O DSLZVSRJTYRBFB-LLEIAEIESA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 208000006825 Eastern Equine Encephalomyelitis Diseases 0.000 description 1
- 201000005804 Eastern equine encephalitis Diseases 0.000 description 1
- 241000710945 Eastern equine encephalitis virus Species 0.000 description 1
- 206010014587 Encephalitis eastern equine Diseases 0.000 description 1
- 206010014611 Encephalitis venezuelan equine Diseases 0.000 description 1
- 206010014614 Encephalitis western equine Diseases 0.000 description 1
- 206010066919 Epidemic polyarthritis Diseases 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 208000025370 Middle East respiratory syndrome Diseases 0.000 description 1
- 241000127282 Middle East respiratory syndrome-related coronavirus Species 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 description 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 241000710942 Ross River virus Species 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 239000004141 Sodium laurylsulphate Substances 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 229920002253 Tannate Polymers 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- 208000002687 Venezuelan Equine Encephalomyelitis Diseases 0.000 description 1
- 201000009145 Venezuelan equine encephalitis Diseases 0.000 description 1
- 108020000999 Viral RNA Proteins 0.000 description 1
- 208000005466 Western Equine Encephalomyelitis Diseases 0.000 description 1
- 201000005806 Western equine encephalitis Diseases 0.000 description 1
- 241000710951 Western equine encephalitis virus Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- VJHCJDRQFCCTHL-UHFFFAOYSA-N acetic acid 2,3,4,5,6-pentahydroxyhexanal Chemical compound CC(O)=O.OCC(O)C(O)C(O)C(O)C=O VJHCJDRQFCCTHL-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical compound [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000004411 aluminium Substances 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 239000003833 bile salt Substances 0.000 description 1
- 229940093761 bile salts Drugs 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000007698 birth defect Effects 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M bisulphate group Chemical group S([O-])(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 239000001527 calcium lactate Substances 0.000 description 1
- MKJXYGKVIBWPFZ-UHFFFAOYSA-L calcium lactate Chemical compound [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 description 1
- 229960002401 calcium lactate Drugs 0.000 description 1
- 235000011086 calcium lactate Nutrition 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- 239000004204 candelilla wax Substances 0.000 description 1
- 235000013868 candelilla wax Nutrition 0.000 description 1
- 229940073532 candelilla wax Drugs 0.000 description 1
- 239000007963 capsule composition Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 229920003123 carboxymethyl cellulose sodium Polymers 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229940105329 carboxymethylcellulose Drugs 0.000 description 1
- 229940084030 carboxymethylcellulose calcium Drugs 0.000 description 1
- 229940063834 carboxymethylcellulose sodium Drugs 0.000 description 1
- 229950008138 carmellose Drugs 0.000 description 1
- 239000004203 carnauba wax Substances 0.000 description 1
- 235000013869 carnauba wax Nutrition 0.000 description 1
- 229940082483 carnauba wax Drugs 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 229960004106 citric acid Drugs 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 229920001531 copovidone Polymers 0.000 description 1
- 229940109275 cyclamate Drugs 0.000 description 1
- HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical compound OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 229960003964 deoxycholic acid Drugs 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 235000013681 dietary sucrose Nutrition 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-M dihydrogenphosphate Chemical compound OP(O)([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-M 0.000 description 1
- 229950010286 diolamine Drugs 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 229940088679 drug related substance Drugs 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 239000003885 eye ointment Substances 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000007888 film coating Substances 0.000 description 1
- 238000009501 film coating Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 229940044170 formate Drugs 0.000 description 1
- 229940050411 fumarate Drugs 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229960001731 gluceptate Drugs 0.000 description 1
- KWMLJOLKUYYJFJ-VFUOTHLCSA-N glucoheptonic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O)C(O)=O KWMLJOLKUYYJFJ-VFUOTHLCSA-N 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 229940097042 glucuronate Drugs 0.000 description 1
- 229960002449 glycine Drugs 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- IUJAMGNYPWYUPM-UHFFFAOYSA-N hentriacontane Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC IUJAMGNYPWYUPM-UHFFFAOYSA-N 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- 229950000177 hibenzate Drugs 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- 239000000832 lactitol Substances 0.000 description 1
- VQHSOMBJVWLPSR-JVCRWLNRSA-N lactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-JVCRWLNRSA-N 0.000 description 1
- 235000010448 lactitol Nutrition 0.000 description 1
- 229960003451 lactitol Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000011344 liquid material Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 229960001078 lithium Drugs 0.000 description 1
- 229960003646 lysine Drugs 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- 229960003194 meglumine Drugs 0.000 description 1
- 238000007909 melt granulation Methods 0.000 description 1
- JZMJDSHXVKJFKW-UHFFFAOYSA-M methyl sulfate(1-) Chemical compound COS([O-])(=O)=O JZMJDSHXVKJFKW-UHFFFAOYSA-M 0.000 description 1
- 238000003801 milling Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 150000004682 monohydrates Chemical class 0.000 description 1
- 231100000243 mutagenic effect Toxicity 0.000 description 1
- 230000003505 mutagenic effect Effects 0.000 description 1
- 125000005487 naphthalate group Chemical group 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- 229950004864 olamine Drugs 0.000 description 1
- 239000006195 ophthalmic dosage form Substances 0.000 description 1
- 229940100688 oral solution Drugs 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- PXQPEWDEAKTCGB-UHFFFAOYSA-N orotic acid Chemical compound OC(=O)C1=CC(=O)NC(=O)N1 PXQPEWDEAKTCGB-UHFFFAOYSA-N 0.000 description 1
- 235000019371 penicillin G benzathine Nutrition 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 229960000502 poloxamer Drugs 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920000193 polymethacrylate Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 239000011118 polyvinyl acetate Substances 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920003124 powdered cellulose Polymers 0.000 description 1
- 235000019814 powdered cellulose Nutrition 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 229940043131 pyroglutamate Drugs 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 239000012056 semi-solid material Substances 0.000 description 1
- 239000008299 semisolid dosage form Substances 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 238000004513 sizing Methods 0.000 description 1
- FHHPUSMSKHSNKW-SMOYURAASA-M sodium deoxycholate Chemical compound [Na+].C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 FHHPUSMSKHSNKW-SMOYURAASA-M 0.000 description 1
- 229940080313 sodium starch Drugs 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- JAJWGJBVLPIOOH-IZYKLYLVSA-M sodium taurocholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 JAJWGJBVLPIOOH-IZYKLYLVSA-M 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 238000000935 solvent evaporation Methods 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 238000005563 spheronization Methods 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 238000009495 sugar coating Methods 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 229910021653 sulphate ion Inorganic materials 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 231100000041 toxicology testing Toxicity 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 229940078499 tricalcium phosphate Drugs 0.000 description 1
- 235000019731 tricalcium phosphate Nutrition 0.000 description 1
- 229910000391 tricalcium phosphate Inorganic materials 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000005550 wet granulation Methods 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
Definitions
- the present invention relates to a pharmaceutical composition, methods for making pharmaceutical formulations comprising Molnupiravir or pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable excipients.
- Molnupiravir is an experimental antiviral drug which is orally active and was developed for the treatment of influenza. It is a prodrug of the synthetic nucleoside derivative N4-hydroxycytidine, and exerts its antiviral action through introduction of copying errors during viral RNA replication. Activity has also been demonstrated against coronaviruses including SARS, MERS and SARS-CoV-2.
- Molnupiravir is reported in US 20200276219 by Emory University A pharmaceutical composition comprising a pharmaceutically acceptable excipient and a compound of Molnupiravir, process for preparation of Molnupiravir and compound of Molnupiravir. But the application does not discuss any details of the pharmaceutical composition.
- the primary Objective of the present invention is a pharmaceutical composition comprising of Molnupiravir or pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable excipient.
- the second objective of the present invention is the process of preparation of pharmaceutical composition of Molnupiravir or pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable excipient.
- Another objective of the present invention is a formulation containing Molnupiravir or a pharmaceutically acceptable salt thereof in a range from about 10 mg to about 800 mg along with and one or more pharmaceutically acceptable excipient.
- Yet another objective of the present invention is preparation of Molnupiravir or oral dosage form about 10 mg to about 800 mg along with and one or more pharmaceutically acceptable excipient.
- Another objective of the present invention is a formulation containing Molnupiravir or a pharmaceutically acceptable salt thereof in a range from about 10 mg to about 800 mg along with and one or more pharmaceutically acceptable excipient where is dosage form exhibits dissolution profile having drug release more than 70% within 30 minutes in 0.1N HC1900ml with 50 rpm.
- Yet another objective of the present invention is preparation of Molnupiravir or oral dosage form about 10 mg to about 800 mg along with and one or more pharmaceutically acceptable excipient.
- This exhibits pharmacokinetic parameters after Single ascending doses where mean Cmax were up to 13.2 ng/mL Tmax is about 0.25 and 0.75 hours and after Multiple ascending doses plasma concentration-time curve dining a dosing interval (AUC ⁇ ) and Cmax between 0.938 and 1.16, and between 0.843 and 1.10, respectively, Median tmax occurred up to 0.75 hours.
- Another objective of the present invention is a formulation comprising Molnupiravir or a pharmaceutically acceptable salt thereof in a range from about 10 mg to about 800 mg along with and one or more pharmaceutically acceptable excipient used for the treatment of viral infection is, or is caused by, an alphavirus, flavivirus or coronaviruses or thomyxoviridae or paramyxoviridae, or RSV, influenza, Powassan virus or filoviridae or Ebola.
- the present invention relates to a pharmaceutical composition, methods for making pharmaceutical composition comprising of Molnupiravir or pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable excipient.
- the term “Molnupiravir” includes the base, pharmaceutically acceptable salts, polymorphs, stereoisomers and mixtures thereof, the term “pharmaceutically acceptable salt” means a salt which is acceptable for administration to a patient, such as a mammal (e.g., salts having acceptable mammalian safety for a given dosage regime). Such salts can be derived from pharmaceutically acceptable inorganic or organic bases and from pharmaceutically acceptable inorganic or organic acids.
- the preferred pharmaceutical composition of the present invention contains various quantities ranging from about 10 mg to about 800 mg of Molnupiravir or a pharmaceutically acceptable salt thereof.
- the preferred formulation can contain about lOmg to 800 mg of Molnupiravir.
- the present invention relates to a pharmaceutical composition and methods for making pharmaceutical formulations comprising Molnupiravir or pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable excipient.
- the present invention further provides process for preparation of Molnupiravir.
- a pharmaceutical composition comprises a pharmaceutically acceptable excipient, such as a pharmaceutically acceptable carrier, and an exemplary compound described herein.
- the pharmaceutical composition comprises, or is in the form of, a pharmaceutically acceptable salt, as generally described below.
- suitable pharmaceutically acceptable organic and/or inorganic acids are hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, acetic acid and citric acid, as well as other pharmaceutically acceptable acids known per se (for which reference is made to the references referred to below).
- the exemplary compounds When the exemplary compounds contain an acidic group as well as a basic group, the compounds can form internal salts, which can also be used in the compositions and methods described herein.
- an exemplary compound contains a hydrogen-donating heteroatom (e.g., NH), salts are contemplated to cover isomers formed by transfer of said hydrogen atom to a basic group or atom within the molecule.
- Pharmaceutically acceptable salts of the exemplary compounds include the acid addition and base salts thereof. Suitable acid addition salts are formed from acids which form non-toxic salts.
- Examples include the acetate, adipate, aspartate, benzoate, besylate, bicarbonate/carbonate, bisulphate/sulphate, borate, camsylate, citrate, cyclamate, edisylate, esylate, formate, fumarate, gluceptate, gluconate, glucuronate, hexafluorophosphate, hibenzate, hydrochloride/chloride, hydrobromide/bromide, hydroiodide/iodide, isethionate, lactate, malate, maleate, malonate, mesylate, methylsulphate, naphthylate, 2-napsylate, nicotinate, nitrate, orotate, oxalate, palmitate, pamoate, phosphate/hydrogen phosphate/dihydrogen phosphate, pyroglutamate, saccharate, stearate, succinate, tannate, tartrate, tosy
- Suitable base salts are formed from bases which form non-toxic salts. Examples include the aluminium, arginine, benzathine, calcium, choline, diethylamine, diolamine, glycine, lysine, magnesium, meglumine, olamine, potassium, sodium, tromethamine and zinc salts. Hemisalts of acids and bases can also be formed, for example, hemisulphate and hemicalcium salts.
- suitable salts see Handbook of Pharmaceutical Salts: Properties, Selection, and Use by Stahl and Wermuth, incorporated herein by reference.
- Physiologically acceptable salts of the exemplary compounds are those that are formed internally in a subject administered compound for the treatment or prevention of disease. Suitable salts include those of lithium, sodium, potassium, magnesium, calcium, manganese, bile salts.
- the present invention relates to a pharmaceutical compositions comprising a pharmaceutically acceptable excipient and a compound disclosed herein, pharmaceutical composition is in the form of Solid dosage form, Semi-solid dosage form, Liquid dosage form, Gaseous dosage form, Oral dosage forms, Topical dosage forms , Parenteral dosage forms, Ophthalmic dosage form,
- compounds described herein can be formulated in a variety of ways.
- Formulations containing one or more compounds can be prepared in various pharmaceutical forms, such as granules, tablets, capsules, suppositories, powders, controlled release formulations, suspensions, emulsions, creams, gels, ointments, salves, lotions, or aerosols and the like.
- the formulations are employed in solid dosage forms suitable for simple, and preferably oral, administration of precise dosages.
- Solid dosage forms for oral administration include, but are not limited to, tablets, soft or hard gelatin or non-gelatin capsules, and caplets.
- liquid dosage forms such as solutions, syrups, suspension, shakes, etc. can also be utilized.
- the formulation is administered topically.
- Suitable topical formulations include, but are not limited to, lotions, ointments, creams, and gels.
- the topical formulation is a gel.
- the formulation is administered intranasal.
- oral dosage forms includes all conventional oral solid dosage forms like a Tablet, capsule, Syrups, Suspension, granules, a pill, a tablet, a caplet, pellets, a powder or a sachet, or any other orally ingestible dosage form comprising Molnupiravir and its salts as an active ingredient mixed with other pharmaceutically acceptable excipients.
- Topical dosage forms includes all conventional oral solid dosage forms like a Ointment, Cream, gels any other Topical dosage form comprising Molnupiravir and its salts as an active ingredient mixed with other pharmaceutically acceptable excipients.
- Parenter dosage forms includes all conventional oral solid dosage forms like a
- Intramuscular injection Intravenous injection, subcutaneous injection any other Parenteral dosage forms comprising Molnupiravir and its salts as an active ingredient mixed with other pharmaceutically acceptable excipients.
- the solid oral pharmaceutical composition is in the form of tablet comprising Molnupiravir or pharmaceutically acceptable salts or derivatives thereof, and one or more pharmaceutically acceptable excipients.
- the solid oral pharmaceutical composition is in the form of capsule comprising Molnupiravir or pharmaceutically acceptable salts or derivatives thereof, and one or more pharmaceutically acceptable excipients.
- the solid oral pharmaceutical composition is in the form of Syrups Suspensions or emulsions comprising Molnupiravir or pharmaceutically acceptable salts or derivatives thereof, and one or more pharmaceutically acceptable excipients.
- parenteral pharmaceutical composition is in the form of Intramuscular injection (or) Intravenous injection (or) subcutaneous injection comprising Molnupiravir pharmaceutically acceptable salts or derivatives thereof, and one or more pharmaceutically acceptable excipients.
- ophthalmic pharmaceutical composition is in the form of eye drops/ophthalmic ointments and gels comprising Molnupiravir or pharmaceutically acceptable salts or derivatives thereof, and one or more pharmaceutically acceptable excipients.
- pharmaceutical acceptable excipients refers to organic or inorganic ingredients, natural or synthetic, with which an active ingredient is combined to facilitate administration of a composition.
- suitable excipients may include, but not limited to the given examples below
- the diluents are used in formulations as a diluting agent or filler or thinner. Diluents are added to ease the restricted movement.
- a preferred further diluent that also causes reduced sticking properties of tablets to the equipment used for tabletting is silica, preferably colloidal or fumed silica.
- the excipients include at least one diluent selected from microcrystalline cellulose and lactosemo no hydrate can be used.
- the binders are used in composition are selected from acacia, starch paste, pregelatinized starch, alginic acid, cellulose, Hydroxy propyl methyl cellulose, poly vinyl pyrolidone, poly ethylene glycol, povidone, acacia, carboxymethyl cellulose sodium, methyl cellulose, ethyl cellulose, liquid glucose, sodium alginate, candelilla wax, carnauba wax, com starch, copovidone, poly ethylene oxide, sodium starch.
- Permeability enhancers are also added to enhance the permeability through cells. They are not limited to following examples SLS, Tween 80, Fatty acid esters (sodium taurocholate, sodium deoxycholate) and the like
- the disintegrant used in the compositions is selected from Alginic acid, citric acid, croscarmellose sodium, Crospovidone, colloidal silicone dioxide, cellulose, carboxy methyl cellulose calcium, micro crystalline cellulose, methyl cellulose, povidone, sodium starch glycolate, Hydroxypropyl methyl cellulose, sodium carmellose, starch, sodium alginate and the like
- the lubricants used in the compositions is selected from stearic acid, magnesium stearate, calcium stearate, sodium lauryl sulphate.
- the excipients include at least one lubricant, selected from stearic acid, magnesium stearate, calcium stearate and sodium stearyl fumarate, more preferably from stearic acid, magnesium stearate and calcium stearate and the like
- the glidants used in the compositions is selected from fumed silica, magnesium carbonate, talc, colloidal silicone dioxide, tri calcium phosphate.
- the pharmaceutical dosage form of the invention can optionally have one or more coatings such as moisture -barrier film coating, sugar coating and other coatings known in the art.
- additives may be selected and used by the skilled artisan having regard to the particular desired properties of the pharmaceutical composition by routine experimentation and without any undue burden.
- the absolute amounts of each additive and the amounts relative to other additives is similarly dependent on the desired properties of the pharmaceutical composition and may also be chosen by the skilled artisan by routine experimentation without undue burden.
- the formulation is a conventional oral solid dosage form, preferably a capsule, granules, a pill, a tablet, a caplet, pellets, a powder or a sachet; and more preferably a capsule, comprising Molnupiravir as an active ingredient mixed with pharmaceutical carriers like diluents, disintegrant, permeability enhancer and amine derivative along with binder, glidant, lubricant which are commonly used.
- the pharmaceutical compositions are prepared by known technological procedures, e.g. direct compression, dry granulation or wet aqueous granulation, using well known and readily available excipients.
- the active ingredient will usually be mixed with an excipient or mixture of excipients, or diluted by an excipient or mixture of excipients, or enclosed within an excipient or mixture of excipients which may be in the form of a capsule, sachet, paper or other container.
- the excipient serves as a diluent, it may be a solid, semisolid or liquid material which acts as a vehicle or medium for the Molnupiravir.
- the composition of the present invention can be produced by sizing and milling a mixture of the drug substance with excipients
- one method for the production includes mixing the Molnupiravir with the materials for the preparation by a suitable mixer, and lubrication the mixture to tablet or capsule.
- the pharmaceutical compositions can be prepared by using any suitable method known in the art such as direct compression, dry or wet granulation (aqueous/non-aqueous or combination), extrusion spheronization, melt extrusion, melt granulation, coating over inert spheres, spray coating, spray drying and solvent evaporation.
- the pharmaceutical composition is meant for once daily or twice daily administration.
- the pharmaceutical composition comprises a solid dispersion of Molnupiravir in one or more carrier and optionally including other pharmaceutically acceptable excipients.
- the solid dispersion may optionally be encapsulated in hard gelatin capsules, compressed into a tablet, or may be granulated with a pharmaceutically acceptable excipients.
- the carrier can be hydrophilic or hydrophobic or water swellable, which include but not limited to polyethylene glycol (PEG), phospholipids, polyvinyl pyrrolidone, cellulose derivatives such as methyl cellulose, carboxymethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methyl cellulose, ethylcellulose, poly (ethylene oxide), carboxyvinyl polymer, Carboxymethylethyl cellulose, polyvinylalcohol and polyvinylacetate (PVA)/PVP copolymer, guar gum, xanthan gum, sodium alginate, dextrin, cyclodextrin, crospovidone, polyacrylates polymethacrylates, urea, soluplus, sugar, polyols and their polymers, surfactants such as poloxamer, tween, gelucire and/or combinations thereof.
- PEG polyethylene glycol
- phospholipids polyvinyl pyrrolidone
- the present invention relates to methods of increasing bioavailability for treating or preventing a viral infection comprising administering an effective amount of a compound or pharmaceutical composition disclosed herein to a subject in need thereof.
- the disclosure relates to methods of treating or preventing a viral infection comprising administering an effective amount of a compound or pharmaceutical composition disclosed herein to a subject in need thereof.
- the viral infection is a Zika virus infection.
- the viral infection is Eastern, Western, and Venezuelan Equine Encephalitis (EEE, WEE and VEE, respectively), Chikungunya fever (CHIK), Ebola, Influenza, or RSV.
- the disclosure relates to methods of treating or preventing a viral infection comprising administering an effective amount of a compound or pharmaceutical composition disclosed herein to a subject in need thereof.
- a method of treating or preventing a Zika virus infection is provided, the method comprising administering an effective amount of a compound or pharmaceutical composition disclosed herein to a subject in need thereof.
- the viral infection is, or is caused by, an alphavirus, flavivirus or coronaviruses orthomyxoviridae or paramyxoviridae, or RSV, influenza, Powassan virus or filoviridae or Ebola.
- the viral infection is, or is caused by, a virus selected from MERS coronavirus, Eastern equine encephalitis virus, Western equine encephalitis virus, Venezuelan equine encephalitis virus, Ross River virus, Barmah Forest virus, Powassan virus, Zika virus, and Chikungunya virus.
- the viral infection is, or is caused by, a Zika virus.
- the terms “prevent” and “preventing” include the prevention of the recurrence, spread or onset. It is not intended that the present disclosure be limited to complete prevention. In some embodiments, the onset is delayed, or the severity of the disease is reduced.
- the terms “treat” and “treating” are not limited to the case where the subject (e.g., patient) is cured and the disease is eradicated. Rather, embodiments, of the present disclosure also contemplate treatment that merely reduces symptoms, and/or delays disease progression.
- the dissolution media used for the test is 900ml of 0.1NHC1 at 50 RPM with paddle.
- Subjects in the food-effect evaluation were randomized in a 1:1 ratio to either 200 mg Molnupiravir in the fed state followed by 200 mg Molnupiravir in the fasted state, or vice versa, with a 14-day washout period between doses.
- a capsule formulation was used in all parts of the study, with the exception of single ascending doses ⁇ 800 mg, where an oral solution formulation was used.
- Concentrations of Molnupiravir were generally not quantifiable and pharmacokinetic parameters were not calculable.
- Concentrations of EIDD-1931 were quantifiable at 0.25 hours post dose for 2 subjects in the fasted state, but no subjects in the fed state. The first quantifiable concentrations in the fed state were between 0.5 and 1.5 hours post dose.
- step-ix and step-x materials Load the granules of step-ix and step-x materials in blender and mix for 10 minutes at slow speed.
- step-ix and step-x materials Load the granules of step-ix and step-x materials in blender and mix for 10 minutes at slow speed.
- Dry Mix Load Step 1 materials in to RMG and mix for 15 minutes at impeller 150 RPM and chopper off.
- Binder Solution preparation Disperse Povidone K 30 in Purified water under stirring.
- Granulation Perform Granulation using contents of step 2 and step 3.
- step 6 Drying: Dry contents of step 5 in Rapid Drier at 50°C temperature until LOD reaches to 1.0% to 3.0%.
- Capsule filling Fill the lubricated blend into suitable size capsules.
- Dry Mix Load Step 1 materials in to RMG and mix for 15 minutes at impeller 150 RPM and chopper off.
- Binder Solution preparation Disperse Povidone K 30 in Purified water under stirring.
- Granulation Perform Granulation using contents of step 2 and step 3.
- step 6 Drying: Dry contents of step 5 in Rapid Drier at 50°C temperature until LOD reaches to 1.0% to 3.0%.
- Capsule filling Fill the lubricated blend into suitable size capsules.
- Dry Mix Load Step 1 materials in to RMG and mix for 15 minutes at impeller 150 RPM and chopper off.
- Binder Solution preparation Disperse Povidone K 30 in Purified water under stirring.
- Granulation Perform Granulation using contents of step 2 and step 3.
- step 6 Drying: Dry contents of step 5 in Rapid Drier at 50°C temperature until LOD reaches to 1.0% to 3.0%.
- Capsule filling Fill the lubricated blend into suitable size capsules.
Abstract
The present invention relates to a pharmaceutical composition, methods for making pharmaceutical formulations comprising Molnupiravir or pharmaceutically acceptable salt or derivatives thereof and one or more pharmaceutically acceptable excipient. The present invention further provides process for preparation of Molnupiravir.
Description
PHARMACEUTICAL COMPOSITION OF MOLNUPIRAVIR
FIELD OF THE INVENTION:
The present invention relates to a pharmaceutical composition, methods for making pharmaceutical formulations comprising Molnupiravir or pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable excipients.
BACKGROUND OF THE INVENTION
Molnupiravir is an experimental antiviral drug which is orally active and was developed for the treatment of influenza. It is a prodrug of the synthetic nucleoside derivative N4-hydroxycytidine, and exerts its antiviral action through introduction of copying errors during viral RNA replication. Activity has also been demonstrated against coronaviruses including SARS, MERS and SARS-CoV-2.
In April 2020 in Chemical & Engineering News (C&EN) Under drug Development section an article titled “An emerging antiviral takes aim at COVID-19” written by Bethany Halford mentioned that, Rick Bright former Head of US Biomedical Advanced Research and Development Authority (BARDA) Rick Bright in his whistle blower complaint revealed concerns over providing funding for the further development of Molnupiravir due to similar drugs having mutagenic properties (producing birth defects). A previous company, Pharmasset that had investigated the drug's active ingredient had abandoned it. These claims were denied by George Painter, CEO of DRIVE, noting that toxicity studies on Molnupiravir had been carried out and data provided to regulators in the US and UK, who permitted safety studies in humans to move forward in the spring of 2020. Also at this time, DRIVE and Ridgeback Bio therapeutics stated they planned future safety studies in animals.
As per the ClinicalTrails.gov data base there were many studies were registered for investigation of Molnupiravir which are as follows:
• On June 16, 2020 Merck Sharp & Dohme Corp, started a clinical study to Evaluate the Safety, Tolerability and Efficacy of EIDD-2801 to Eliminate Infectious Virus Detection in Persons With COVID-19
• March 2020, many of the human clinical trials were being done of the Molnupiravir for "Safety, Tolerability, and Pharmacokinetics" in healthy volunteers in the UK and US.
• In June 2020, Ridgeback Bio therapeutics announced it was moving to Phase II trials to test the efficacy of the drug as a treatment for COVID-19. Two trials of small numbers of hospitalized and non-hospitalized patients in the US and the UK were underway in July.
• In late July 2020, and without yet releasing any medical data, Merck, which had been partnering with Ridgeback Bio therapeutics on developing the drug, announced its intention to move Molnupiravir to late stage trials beginning in September 2020.
• On October 19, 2020 recruiting of human volunteers for the interventional clinical trial was started for phase 2/3, randomized, placebo-controlled, double-blind clinical study, in which the efficacy, safety, and pharmacokinetics of mk-4482 in hospitalized adults with covid-19.
On December 3rd, 2020, an article was published in the journal “Nature” on the results of a study on the treatment with Molnupiravir of ferrets infected with Covid-19. The study found that the drug was "efficacious" when administered orally to infected ferrets, and that it blocked the transmission of the virus between ferrets after 24 hours following administration of the drug.
Molnupiravir is reported in US 20200276219 by Emory University A pharmaceutical composition comprising a pharmaceutically acceptable excipient and a compound of Molnupiravir, process for preparation of Molnupiravir and compound of Molnupiravir. But the application does not discuss any details of the pharmaceutical composition.
Nowhere is the above mentioned state of arts there is disclosure of any pharmaceutical composition nor process of preparation of the pharmaceutical composition of Molnupiravir or its suitable dosage forms were discussed, hence there is an immense need of present invention for a detailed disclosure of Molnupiravir pharmaceutical composition and its processes of preparation of same.
OBJECTIVES OF THE INVENTION
The primary Objective of the present invention is a pharmaceutical composition comprising of Molnupiravir or pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable excipient.
The second objective of the present invention is the process of preparation of pharmaceutical composition of Molnupiravir or pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable excipient.
Another objective of the present invention is a formulation containing Molnupiravir or a pharmaceutically acceptable salt thereof in a range from about 10 mg to about 800 mg along with and one or more pharmaceutically acceptable excipient.
Yet another objective of the present invention is preparation of Molnupiravir or oral dosage form about 10 mg to about 800 mg along with and one or more pharmaceutically acceptable excipient.
Another objective of the present invention is a formulation containing Molnupiravir or a pharmaceutically acceptable salt thereof in a range from about 10 mg to about 800 mg along with and one or more pharmaceutically acceptable excipient where is dosage form exhibits dissolution profile having drug release more than 70% within 30 minutes in 0.1N HC1900ml with 50 rpm.
Yet another objective of the present invention is preparation of Molnupiravir or oral dosage form about 10 mg to about 800 mg along with and one or more pharmaceutically acceptable excipient. This exhibits pharmacokinetic parameters after Single ascending doses where mean Cmax were up to 13.2 ng/mL Tmax is about 0.25 and 0.75 hours and after Multiple ascending doses plasma concentration-time curve dining a dosing interval (AUCτ) and Cmax between 0.938 and 1.16, and between 0.843 and 1.10, respectively, Median tmax occurred up to 0.75 hours.
Another objective of the present invention is a formulation comprising Molnupiravir or a pharmaceutically acceptable salt thereof in a range from about 10 mg to about 800 mg along with and one or more pharmaceutically acceptable excipient used for the treatment of viral infection is, or is caused by, an alphavirus, flavivirus or coronaviruses or thomyxoviridae or paramyxoviridae, or RSV, influenza, Powassan virus or filoviridae or Ebola.
SUMMARY OF THE INVENTION
The present invention relates to a pharmaceutical composition, methods for making pharmaceutical composition comprising of Molnupiravir or pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable excipient.
As used herein, the term “Molnupiravir" includes the base, pharmaceutically acceptable salts, polymorphs, stereoisomers and mixtures thereof, the term "pharmaceutically acceptable salt" means a salt which is acceptable for administration to a patient, such as a mammal (e.g., salts having acceptable mammalian safety for a given dosage regime). Such salts can be derived from pharmaceutically acceptable inorganic or organic bases and from pharmaceutically acceptable inorganic or organic acids.
Accordingly, the preferred pharmaceutical composition of the present invention contains various quantities ranging from about 10 mg to about 800 mg of Molnupiravir or a pharmaceutically acceptable salt thereof. Thus, for example, the preferred formulation can contain about lOmg to 800 mg of Molnupiravir.
DETAILED DESCRIPTION OF THE INVENTION
The present invention relates to a pharmaceutical composition and methods for making pharmaceutical formulations comprising Molnupiravir or pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable excipient. The present invention further provides process for preparation of Molnupiravir.
In embodiments, a pharmaceutical composition comprises a pharmaceutically acceptable excipient, such as a pharmaceutically acceptable carrier, and an exemplary compound described herein.
In certain exemplary embodiments, the pharmaceutical composition comprises, or is in the form of, a pharmaceutically acceptable salt, as generally described below. Some preferred, but non-limiting examples of suitable pharmaceutically acceptable organic and/or inorganic acids are hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, acetic acid and citric acid, as well as other pharmaceutically acceptable acids known per se (for which reference is made to the references referred to below).
When the exemplary compounds contain an acidic group as well as a basic group, the compounds can form internal salts, which can also be used in the compositions and methods described herein. When an exemplary compound contains a hydrogen-donating heteroatom (e.g., NH), salts are contemplated to cover isomers formed by transfer of said hydrogen atom to a basic group or atom within the molecule. Pharmaceutically acceptable salts of the exemplary compounds include the acid addition and base salts
thereof. Suitable acid addition salts are formed from acids which form non-toxic salts. Examples include the acetate, adipate, aspartate, benzoate, besylate, bicarbonate/carbonate, bisulphate/sulphate, borate, camsylate, citrate, cyclamate, edisylate, esylate, formate, fumarate, gluceptate, gluconate, glucuronate, hexafluorophosphate, hibenzate, hydrochloride/chloride, hydrobromide/bromide, hydroiodide/iodide, isethionate, lactate, malate, maleate, malonate, mesylate, methylsulphate, naphthylate, 2-napsylate, nicotinate, nitrate, orotate, oxalate, palmitate, pamoate, phosphate/hydrogen phosphate/dihydrogen phosphate, pyroglutamate, saccharate, stearate, succinate, tannate, tartrate, tosylate, trifluoroacetate and xinofoate salts. Suitable base salts are formed from bases which form non-toxic salts. Examples include the aluminium, arginine, benzathine, calcium, choline, diethylamine, diolamine, glycine, lysine, magnesium, meglumine, olamine, potassium, sodium, tromethamine and zinc salts. Hemisalts of acids and bases can also be formed, for example, hemisulphate and hemicalcium salts. For a review on suitable salts, see Handbook of Pharmaceutical Salts: Properties, Selection, and Use by Stahl and Wermuth, incorporated herein by reference. Physiologically acceptable salts of the exemplary compounds are those that are formed internally in a subject administered compound for the treatment or prevention of disease. Suitable salts include those of lithium, sodium, potassium, magnesium, calcium, manganese, bile salts.
The present invention relates to a pharmaceutical compositions comprising a pharmaceutically acceptable excipient and a compound disclosed herein, pharmaceutical composition is in the form of Solid dosage form, Semi-solid dosage form, Liquid dosage form, Gaseous dosage form, Oral dosage forms, Topical dosage forms , Parenteral dosage forms, Ophthalmic dosage form,
In certain embodiments compounds described herein can be formulated in a variety of ways. Formulations containing one or more compounds can be prepared in various pharmaceutical forms, such as granules, tablets, capsules, suppositories, powders, controlled release formulations, suspensions, emulsions, creams, gels, ointments, salves, lotions, or aerosols and the like. In certain embodiments, the formulations are employed in solid dosage forms suitable for simple, and preferably oral, administration of precise dosages. Solid dosage forms for oral administration include, but are not limited to, tablets, soft or hard gelatin or non-gelatin capsules, and caplets. However, liquid dosage forms, such as solutions, syrups, suspension, shakes, etc. can also be utilized. In another embodiment, the formulation is administered topically. Suitable topical formulations include, but are not limited to, lotions, ointments, creams, and gels. In a preferred embodiment, the topical formulation is a gel. In another embodiment, the formulation is administered intranasal.
It must be noted that, as used in the specification and the appended claims, the singular forms "a," "an," and "the" include plural referents unless the context clearly dictates otherwise.
The term "oral dosage forms" includes all conventional oral solid dosage forms like a Tablet, capsule, Syrups, Suspension, granules, a pill, a tablet, a caplet, pellets, a powder or a sachet, or any other orally ingestible dosage form comprising Molnupiravir and its salts as an active ingredient mixed with other pharmaceutically acceptable excipients.
The term "Topical dosage forms " includes all conventional oral solid dosage forms like a Ointment, Cream, gels any other Topical dosage form comprising Molnupiravir and its salts as an active ingredient mixed with other pharmaceutically acceptable excipients.
The term "Parenteral dosage forms” includes all conventional oral solid dosage forms like a
Intramuscular injection, Intravenous injection, subcutaneous injection any other Parenteral dosage forms comprising Molnupiravir and its salts as an active ingredient mixed with other pharmaceutically acceptable excipients.
In another embodiment, the solid oral pharmaceutical composition is in the form of tablet comprising Molnupiravir or pharmaceutically acceptable salts or derivatives thereof, and one or more pharmaceutically acceptable excipients.
In another embodiment, the solid oral pharmaceutical composition is in the form of capsule comprising Molnupiravir or pharmaceutically acceptable salts or derivatives thereof, and one or more pharmaceutically acceptable excipients.
In another embodiment, the solid oral pharmaceutical composition is in the form of Syrups Suspensions or emulsions comprising Molnupiravir or pharmaceutically acceptable salts or derivatives thereof, and one or more pharmaceutically acceptable excipients.
In another embodiment, the parenteral pharmaceutical composition is in the form of Intramuscular injection (or) Intravenous injection (or) subcutaneous injection comprising Molnupiravir pharmaceutically acceptable salts or derivatives thereof, and one or more pharmaceutically acceptable excipients.
In another embodiment, the ophthalmic pharmaceutical composition is in the form of eye drops/ophthalmic ointments and gels comprising Molnupiravir or pharmaceutically acceptable salts or derivatives thereof, and one or more pharmaceutically acceptable excipients.
The term "pharmaceutical acceptable excipients" used herein, refers to organic or inorganic ingredients, natural or synthetic, with which an active ingredient is combined to facilitate administration of a composition. Examples of suitable excipients may include, but not limited to the given examples below
According to the embodiments, the diluents are used in formulations as a diluting agent or filler or thinner. Diluents are added to ease the restricted movement. In the current invention microcrystalline cellulose, powdered cellulose, lactose (anhydrous or monohydrate), compressible sugar, fructose, dextranes, other sugars such as mannitol, sorbitol, lactitol, saccharose or a mixture thereof, siliconised microcrystalline cellulose, calcium hydrogen phosphate, calcium carbonate, calcium lactate or mixtures thereof. A preferred further diluent that also causes reduced sticking properties of tablets to the equipment used for tabletting is silica, preferably colloidal or fumed silica. Preferably, the excipients include at least one diluent selected from microcrystalline cellulose and lactosemo no hydrate can be used.
According to the embodiments, the binders are used in composition are selected from acacia, starch paste, pregelatinized starch, alginic acid, cellulose, Hydroxy propyl methyl cellulose, poly vinyl pyrolidone, poly ethylene glycol, povidone, acacia, carboxymethyl cellulose sodium, methyl cellulose, ethyl cellulose, liquid glucose, sodium alginate, candelilla wax, carnauba wax, com starch, copovidone, poly ethylene oxide, sodium starch. Permeability enhancers are also added to enhance the permeability through cells. They are not limited to following examples SLS, Tween 80, Fatty acid esters (sodium taurocholate, sodium deoxycholate) and the like
According to the embodiment, the disintegrant used in the compositions is selected from Alginic acid, citric acid, croscarmellose sodium, Crospovidone, colloidal silicone dioxide, cellulose, carboxy methyl cellulose calcium, micro crystalline cellulose, methyl cellulose, povidone, sodium starch glycolate, Hydroxypropyl methyl cellulose, sodium carmellose, starch, sodium alginate and the like
According to the embodiment, the lubricants used in the compositions is selected from stearic acid, magnesium stearate, calcium stearate, sodium lauryl sulphate.
Preferred that the excipients include at least one lubricant, selected from stearic acid, magnesium stearate, calcium stearate and sodium stearyl fumarate, more preferably from stearic acid, magnesium stearate and calcium stearate and the like
According to the embodiment, the glidants used in the compositions is selected from fumed silica, magnesium carbonate, talc, colloidal silicone dioxide, tri calcium phosphate. The pharmaceutical dosage form of the invention can optionally have one or more coatings such as moisture -barrier film coating, sugar coating and other coatings known in the art.
One or more of these additives may be selected and used by the skilled artisan having regard to the particular desired properties of the pharmaceutical composition by routine experimentation and without any undue burden. The absolute amounts of each additive and the amounts relative to other additives is similarly dependent on the desired properties of the pharmaceutical composition and may also be chosen by the skilled artisan by routine experimentation without undue burden.
According to one of the embodiments of the present invention, the formulation is a conventional oral solid dosage form, preferably a capsule, granules, a pill, a tablet, a caplet, pellets, a powder or a sachet; and more preferably a capsule, comprising Molnupiravir as an active ingredient mixed with pharmaceutical carriers like diluents, disintegrant, permeability enhancer and amine derivative along with binder, glidant, lubricant which are commonly used.
In further embodiments of the present invention, the pharmaceutical compositions are prepared by known technological procedures, e.g. direct compression, dry granulation or wet aqueous granulation, using well known and readily available excipients. In the preparation of the compositions of Molnupiravir, the active ingredient will usually be mixed with an excipient or mixture of excipients, or diluted by an excipient or mixture of excipients, or enclosed within an excipient or mixture of excipients which may be in the form of a capsule, sachet, paper or other container. When the excipient serves as a diluent, it may be a solid, semisolid or liquid material which acts as a vehicle or medium for the Molnupiravir.
The composition of the present invention can be produced by sizing and milling a mixture of the drug substance with excipients For example, one method for the production includes mixing the Molnupiravir with the materials for the preparation by a suitable mixer, and lubrication the mixture to tablet or capsule.
The pharmaceutical compositions can be prepared by using any suitable method known in the art such as direct compression, dry or wet granulation (aqueous/non-aqueous or combination), extrusion spheronization, melt extrusion, melt granulation, coating over inert spheres, spray coating, spray drying and solvent evaporation.
The pharmaceutical composition is meant for once daily or twice daily administration. According to one embodiment, the pharmaceutical composition comprises a solid dispersion of Molnupiravir in one or more carrier and optionally including other pharmaceutically acceptable excipients. The solid dispersion may optionally be encapsulated in hard gelatin capsules, compressed into a tablet, or may be granulated with a pharmaceutically acceptable excipients. The carrier can be hydrophilic or hydrophobic or water swellable, which include but not limited to polyethylene glycol (PEG), phospholipids, polyvinyl pyrrolidone, cellulose derivatives such as methyl cellulose, carboxymethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methyl cellulose, ethylcellulose, poly (ethylene oxide), carboxyvinyl polymer, Carboxymethylethyl cellulose, polyvinylalcohol and polyvinylacetate (PVA)/PVP copolymer, guar gum, xanthan gum, sodium alginate, dextrin, cyclodextrin, crospovidone, polyacrylates polymethacrylates, urea, soluplus, sugar, polyols and their polymers, surfactants such as poloxamer, tween, gelucire and/or combinations thereof.
In certain embodiments, the present invention relates to methods of increasing bioavailability for treating or preventing a viral infection comprising administering an effective amount of a compound or pharmaceutical composition disclosed herein to a subject in need thereof.
In certain embodiments, the disclosure relates to methods of treating or preventing a viral infection comprising administering an effective amount of a compound or pharmaceutical composition disclosed herein to a subject in need thereof. In certain embodiments, the viral infection is a Zika virus infection. In other embodiments, the viral infection is Eastern, Western, and Venezuelan Equine Encephalitis (EEE, WEE and VEE, respectively), Chikungunya fever (CHIK), Ebola, Influenza, or RSV.
In certain embodiments, the disclosure relates to methods of treating or preventing a viral infection comprising administering an effective amount of a compound or pharmaceutical composition disclosed herein to a subject in need thereof. In certain exemplary embodiments, a method of treating or preventing a Zika virus infection is provided, the method comprising administering an effective amount of a compound or pharmaceutical composition disclosed herein to a subject in need thereof.
In certain embodiments, the viral infection is, or is caused by, an alphavirus, flavivirus or coronaviruses orthomyxoviridae or paramyxoviridae, or RSV, influenza, Powassan virus or filoviridae or Ebola.
In certain embodiments, the viral infection is, or is caused by, a virus selected from MERS coronavirus, Eastern equine encephalitis virus, Western equine encephalitis virus, Venezuelan equine encephalitis virus, Ross River virus, Barmah Forest virus, Powassan virus, Zika virus, and Chikungunya virus. In certain exemplary embodiments, the viral infection is, or is caused by, a Zika virus.
As used herein, the terms “prevent” and “preventing” include the prevention of the recurrence, spread or onset. It is not intended that the present disclosure be limited to complete prevention. In some embodiments, the onset is delayed, or the severity of the disease is reduced.
As used herein, the terms “treat” and “treating” are not limited to the case where the subject (e.g., patient) is cured and the disease is eradicated. Rather, embodiments, of the present disclosure also contemplate treatment that merely reduces symptoms, and/or delays disease progression.
IN-VITRO DISSOLUTION STUDIES:
Dissolution study of test product Molnupiravir Capsules 200 mg, 400mg 800 mg was performed in order to understand % dissolution in release dissolution media. The dissolution media used for the test is 900ml of 0.1NHC1 at 50 RPM with paddle.
Dissolution Profiles:
Pharmacokinetic Parameters as disclosed by the innovator Bio studies:
Single and multiple doses of Molnupiravir were evaluated in this first-in-human, phase 1, 20 randomized, double-blind, placebo-controlled study in healthy volunteers, which included 21 evaluation of the effect of food on pharmacokinetics. Eligible subjects were randomized in a 3:1 ratio to either study drug or placebo in the single- and multiple-ascending-dose parts of the study. Each cohort comprised 8 subjects, with single oral doses of 50 to 1600 mg administered in the single-ascending- dose part and twice-daily (BID) 107 doses of 50 to 800 mg administered for 5.5 days in the multiple- ascending-dose part. Subjects were followed for 14 days following completion of dosing for assessments of safety, tolerability, and pharmacokinetics. Subjects in the food-effect evaluation were randomized in a 1:1 ratio to either 200 mg Molnupiravir in the fed state followed by 200 mg Molnupiravir in the fasted state, or vice versa, with a 14-day washout period between doses. A capsule
formulation was used in all parts of the study, with the exception of single ascending doses ≤800 mg, where an oral solution formulation was used.
On Day 1, when assessed using the power model, mean Cmax and AUCinf increased in an approximately dose-proportional manner. However, the upper bound of the 90% confidence interval for Cmax was slightly below unity and the lower bound of the 90% confidence interval for AUCinf was slightly above unity (Table 7). On Day 6, mean Cmax increased in a dose proportional manner, with the 90% confidence interval containing unity. Similarly, mean AUCτ increased in an approximately dose- proportional manner; however, the lower bound of the 90% confidence interval was slightly above unity.
Effect tit Food on Molnupiravir Absorption:
Concentrations of Molnupiravir were generally not quantifiable and pharmacokinetic parameters were not calculable. Concentrations of EIDD-1931 were quantifiable at 0.25 hours post dose for 2 subjects in the fasted state, but no subjects in the fed state. The first quantifiable concentrations in the fed state were between 0.5 and 1.5 hours post dose.
200 mg molnupiravir capsule (fasted) 200 mg molnupiravir capsule (fed)
The above bio-studies data has been obtained from article published by Ridgeback Bio therapeutics (Antimicrob Agents Chemother, 2021 Mar l;65(5):e02428-20.).
Clinical Study data:
The applicant of the instant invention as performed a multicentre, open label, randomized study to assess the efficacy and safety of Molnupiravir 800 mg (BID) + Standard of Care (SOC) and Standard of Care (SOC) only, in mild Covid patients.
In the above said study Patients with RT-PCR confirmed COVID-19 and satisfying all the inclusion and none of the exclusion criteria were identified and screened for the study. Eligible patients were randomized (1:1) either to receive Molnupiravir 800 mg (BID) + Standard of Care or Standard of Care only for 5 days. End of treatment assessment was performed on Day 5 (+1).
The interim results indicate that addition of Molnupiravir to SOC results in significantly faster clinical improvement in terms of reduction in score on WHO ordinal scale and also results in faster reduction of viral load as indicated by significant increase in CT values of RT-PCR tests as well as significantly higher proportion of patients achieving RT-PCR negativity on days 5 and 10. Additionally, the number of SAEs reported in the subjects who received Molnupiravir + SoC were significantly lesser, as compared to the subjects who received SoC alone. This shows that the Molnupiravir (800mg) capsule when given along with SoC increases the effectiveness as well as safety of the treatment in subjects with mild Covid-19.
EXAMPLES
The following examples are included to further illustrate the present invention. It should not be regarded as a limitation on the present invention.
Brief Manufacturing process
Co-sift Molnupiravir, Hydroxypropyl cellulose.
Load sifted materials of step-i in Rapid Mixer Granulator and dry mix for 15 minutes.
Dissolve Pregelatinized starch in purified water under stirring and continue stirring till get clear solution. Granulate the dry mix material of step-ii using binder solution of step iii.
Unload the wet mass from RMG of step-iv and mill through co-mill fitted with 3.0 mm screen at medium speed.
Sift sodium stearyl fumarate through sieve.
Load the granules of step-ix and step-x materials in blender and mix for 10 minutes at slow speed.
Brief Manufacturing nr
Co-sift Molnupiravir, Hydroxypropyl cellulose.
1. Load sifted materials of step-i in Rapid Mixer Granulator and dry mix for 15 minutes.
2. Dissolve Pregelatinized starch in purified water under stirring and continue stirring till get clear solution.
3. Granulate the dry mix material of step-ii using binder solution of step iii.
4. Unload the wet mass from RMG of step-iv and mill through co-mill fitted with 3.0 mm screen at medium speed.
5. Sift sodium stearyl fumarate through sieve.
6. Load the granules of step-ix and step-x materials in blender and mix for 10 minutes at slow speed.
Brief Manufacturing process
1. Co-sift Molnupiravir, Hydroxy propyl cellulose.
2. Load sifted materials of step-i in Rapid Mixer Granulator and dry mix for 15 minutes.
3. Dissolve Pregelatinized starch in purified water under stirring and continue stirring till get clear solution.
4. Granulate the dry mix material of step-ii using binder solution of step iii.
5. Unload the wet mass from RMG of step-iv and mill through co-mill fitted with 3.0 mm screen at medium speed.
6. Sift sodium stearyl fumarate through sieve.
7. Load the granules of step-ix and step-x materials in blender and mix for 10 minutes at slow speed.
Brief Manufacturing nr
1. Sifting: Sift Molnupiravir and Crospovidone, through # 30 mesh.
2. Dry Mix: Load Step 1 materials in to RMG and mix for 15 minutes at impeller 150 RPM and chopper off.
3. Binder Solution preparation: Disperse Povidone K 30 in Purified water under stirring.
4. Granulation: Perform Granulation using contents of step 2 and step 3.
5. Wet Milling: Mill Granules of step 4 through 3 mm screen.
6. Drying: Dry contents of step 5 in Rapid Drier at 50°C temperature until LOD reaches to 1.0% to 3.0%.
7. Sizing and Milling: Seive contents of step 6 through # 24 mesh and mill retentions through 1-00 mm until all the material passed through # 24 mesh.
8. Extragranular Sifting: a. Sift Colloidal Silicon dioxide through # 24 mesh b. Sift Sodium Stearyl Fumarate through # 60 mesh.
9. Lubrication: a. Load contents of step 7 and step 8 (a) into blender and mix for 10 minutes. b. Add contents of Step 8 (b) to contents of step 9 (a) and mix for 5 minutes.
10. Capsule filling: Fill the lubricated blend into suitable size capsules.
1. Sifting: Sift Molnupiravir and Crospovidone, through # 30 mesh.
2. Dry Mix: Load Step 1 materials in to RMG and mix for 15 minutes at impeller 150 RPM and chopper off.
3. Binder Solution preparation: Disperse Povidone K 30 in Purified water under stirring.
4. Granulation: Perform Granulation using contents of step 2 and step 3.
5. Wet Milling: Mill Granules of step 4 through 3 mm screen.
6. Drying: Dry contents of step 5 in Rapid Drier at 50°C temperature until LOD reaches to 1.0% to 3.0%.
7. Sizing and Milling: Seive contents of step 6 through # 24 mesh and mill retentions through 1-00 mm until all the material passed through # 24 mesh.
8. Extragranular Sifting: a. Sift Colloidal Silicon dioxide through # 24 mesh b. Sift Sodium Stearyl Fumarate through # 60 mesh.
9. Lubrication: a. Load contents of step 7 and step 8 (a) into blender and mix for 10 minutes. b. Add contents of Step 8 (b) to contents of step 9 (a) and mix for 5 minutes.
10. Capsule filling: Fill the lubricated blend into suitable size capsules.
Brief Manufacturing process
1. Sifting: Sift Molnupiravir and Crospovidone, through # 30 mesh.
2. Dry Mix: Load Step 1 materials in to RMG and mix for 15 minutes at impeller 150 RPM and chopper off.
3. Binder Solution preparation: Disperse Povidone K 30 in Purified water under stirring.
4. Granulation: Perform Granulation using contents of step 2 and step 3.
5. Wet Milling: Mill Granules of step 4 through 3 mm screen.
6. Drying: Dry contents of step 5 in Rapid Drier at 50°C temperature until LOD reaches to 1.0% to 3.0%.
7. Sizing and Milling: Seive contents of step 6 through # 24 mesh and mill retentions through 1-00 mm untill all the material passed through # 24 mesh.
8. Extragranular Sifting: a. Sift Colloidal Silicon dioxide through # 24 mesh b. Sift Sodium Stearyl Fumarate through # 60 mesh.
9. Lubrication: a. Load contents of step 7 and step 8 (a) into blender and mix for 10 minutes. b. Add contents of Step 8 (b) to contents of step 9 (a) and mix for 5 minutes.
10. Capsule filling: Fill the lubricated blend into suitable size capsules.
Claims
1. A pharmaceutical composition comprising of Molnupiravir or pharmaceutically acceptable salt thereof in the range of about 10 mg to about 800 mg along with one or more pharmaceutically acceptable excipients.
2. The pharmaceutical composition as claimed in claim 1, wherein Molnupiravir salts are equivalent to Molnupiravir in a range from about 10 mg to about 800 mg along with and one or more pharmaceutically acceptable excipient.
3. The pharmaceutical composition as claimed in claim 1 , wherein the composition is oral dosage form.
4. The pharmaceutical composition as claimed in claim 4, wherein the oral dosage form is in the form of Tablet, capsule, Syrups, Suspension, granules, a pill, a tablet, a caplet, pellets, a powder or a sachet, or any other orally ingestible dosage form.
5. The pharmaceutical composition as claimed in claim 4, where the oral dosage form is more preferably capsule dosage form.
6. The pharmaceutical composition as claimed in claim 1, wherein the pharmaceutically acceptable excipients are selected from a diluent, a disintegrant, a colorant, a binder, a glidant, a lubricant and the like or mixture thereof.
7. The pharmaceutical composition as claimed in claim 6, wherein preferably excipients are selected from microcrystalline cellulose, croscarmellose sodium, iron oxide yellow, povidone K-30, colloidal silicon dioxide, magnesium stearate and the like or mixture thereof and optionally a pharmaceutical acceptable excipient.
8. A pharmaceutical composition comprising of Molnupiravir or pharmaceutically acceptable salt thereof wherein the pharmaceutical composition comprising of one or more using pharmaceutical acceptable excipient selected from the group of binders or/and Lubricants.
9. The pharmaceutical composition comprising of Molnupiravir claimed in claim 8 wherein the binders are selected from but not limited to Acacia, povidone, starch derivatives, cellulose
derivatives or combination thereof; wherein the lubricants are selected from but not limited to stearic acid, magnesium stearate, calcium stearate and sodium stearyl fumarate, more preferably from stearic acid, magnesium stearate and calcium stearate and the like.
10. The pharmaceutical composition comprising of Molnupiravir claimed in claim 8 The pharmaceutical composition as claimed in claim 1, wherein composition comprising of Molnupiravir or a pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable excipient used for the treatment of viral infection is, or is caused by, an alphavirus, flavivirus or coronaviruses orthomyxoviridae or paramyxoviridae, or RSV, influenza, Powassan virus or filoviridae or Ebola.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN202141013918 | 2021-03-29 | ||
IN202141013918 | 2021-03-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022208156A1 true WO2022208156A1 (en) | 2022-10-06 |
Family
ID=83458143
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2021/058519 WO2022208156A1 (en) | 2021-03-29 | 2021-09-18 | Pharmaceutical composition of molnupiravir |
Country Status (2)
Country | Link |
---|---|
TW (1) | TW202237145A (en) |
WO (1) | WO2022208156A1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115429770A (en) * | 2022-10-11 | 2022-12-06 | 安徽贝克生物制药有限公司 | Monapilavi pharmaceutical composition with good stability and preparation method thereof |
WO2023070058A1 (en) * | 2021-10-20 | 2023-04-27 | Merck Sharp & Dohme Llc | Treatment of viruses with antiviral nucleosides |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20200276219A1 (en) * | 2017-12-07 | 2020-09-03 | Emory University | N4-hydroxycytidine and derivatives and anti-viral uses related thereto |
-
2021
- 2021-09-18 WO PCT/IB2021/058519 patent/WO2022208156A1/en active Application Filing
- 2021-10-15 TW TW110138408A patent/TW202237145A/en unknown
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20200276219A1 (en) * | 2017-12-07 | 2020-09-03 | Emory University | N4-hydroxycytidine and derivatives and anti-viral uses related thereto |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023070058A1 (en) * | 2021-10-20 | 2023-04-27 | Merck Sharp & Dohme Llc | Treatment of viruses with antiviral nucleosides |
CN115429770A (en) * | 2022-10-11 | 2022-12-06 | 安徽贝克生物制药有限公司 | Monapilavi pharmaceutical composition with good stability and preparation method thereof |
Also Published As
Publication number | Publication date |
---|---|
TW202237145A (en) | 2022-10-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPH0122245B2 (en) | ||
US11925709B2 (en) | Tablet formulation for CGRP active compounds | |
JP2013525480A (en) | Immediate release formulation and dosage form of γ-hydroxybutyrate | |
TR201809084T4 (en) | Solid pharmaceutical dosage formulation containing lopinavir. | |
HUE031177T2 (en) | Solid pharmaceutical composition comprising rivaroxaban | |
KR20130116164A (en) | Oral dosage forms of bendamustine and therapeutic use thereof | |
WO2022208156A1 (en) | Pharmaceutical composition of molnupiravir | |
AU2014315110A1 (en) | Corticosteroid containing orally disintegrating tablet compositions for eosinophilic esophagitis | |
JP2003528905A (en) | Stavudine-containing sustained release beads | |
EP2514422B1 (en) | Elution stabilized teneligliptin preparation | |
JP2022123032A (en) | Edaravone pharmaceutical composition | |
KR20120089817A (en) | Solid dispersion comprising celecoxib with improved bioavailibity, pharmaceutical composition comprising the solid dispersion, and preparation method of the solid dispersion | |
JP2021512869A (en) | Oral preparation and its use | |
EP2701689B1 (en) | Pharmaceutical compositions of raltegravir, methods of preparation and use thereof | |
US20150283248A1 (en) | Pharmaceutical compositions of Linagliptin and process for preparation thereof | |
WO2005046697A1 (en) | Sustained-release phenylalanine derivative preparation for oral administration | |
EP3429562A1 (en) | Compositions of deferasirox | |
EP4048276B1 (en) | Solid pharmaceutical formulations comprising ticagrelor | |
TR202014694A1 (en) | ELTROMBOPAG A SOLID ORAL PHARMACEUTICAL FORMULATION CONTAINING OLAMINE | |
TW202045148A (en) | Pharmaceutical compostion containing acetaminophen and ibuprofen | |
JP2014522856A (en) | Stable dosage forms of Alterolane and Piperaquin | |
JP2003300872A (en) | Coated solid hypnotic preparation | |
WO2008068778A2 (en) | Extended release pharmaceutical composition of pramipexole | |
US11260055B2 (en) | Oral pharmaceutical composition of lurasidone and preparation thereof | |
JPS63267720A (en) | Sustained release preparation of emorfazone |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21934738 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 21934738 Country of ref document: EP Kind code of ref document: A1 |